Status:
RECRUITING
Diagnosis, Prognosis, and Mechanisms in Panvascular Disease
Lead Sponsor:
Jinwei Tian
Conditions:
Panvascular Diseases
Cardiovascular Diseases
Eligibility:
All Genders
18-80 years
Brief Summary
This study aims to establish a standardized cohort for panvascular diseases, encompassing biological materials such as DNA samples, along with extensive patient medical records and follow-up informati...
Detailed Description
Panvascular diseases are a group of complex disorders affecting the entire vascular system, with their development influenced by multiple risk factors, including genetic susceptibility, metabolic abno...
Eligibility Criteria
Inclusion
- Male or female aged 18 to 80 years old;
- Diagnosed or suspected panvascular disease, defined as the presence of atherosclerotic lesions in at least two or more vascular regions, such as intracranial arteries, carotid arteries, coronary arteries, aorta, and peripheral arteries;
- Voluntary participation in this study and provision of signed informed consent.
Exclusion
- Severe hemodynamic instability;
- Severe cardiac dysfunction (EF \< 30%);
- Severe arrhythmias;
- Severe valvular heart disease;
- Cardiomyopathy caused by non-coronary artery diseases;
- Non-atherosclerotic coronary artery disease (e.g., coronary artery dissection, embolism, etc.);
- Severe non-cardiovascular diseases;
- Women who are pregnant or breastfeeding;
- Individuals who refuse to provide signed informed consent.
Key Trial Info
Start Date :
December 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT07151183
Start Date
December 1 2024
End Date
December 31 2030
Last Update
September 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Harbin Medical University
Harbin, Heilongjiang, China, 150086